

Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-10. (canceled)

11. (currently amended) A method for treating a cardiac muscle disorder myocardiopathy, comprising administering a therapeutically effective amount of a nucleic acid molecule encoding HGF directly to a part of an affected abdominal lateral cardiac muscle of a mammal using echocardiographic guidance without thoracotomy, wherein the nucleic acid molecule ~~comprises~~ is encapsulated in a Sendai virus (HVJ)-liposome and expresses an HGF protein that reduces fibrosis and/or promotes angiogenesis of the cardiac muscle, thereby treating the cardiac muscle disorder myocardiopathy.

12.-13. (canceled)

14. (currently amended) A method for treating a cardiac muscle disorder myocardiopathy, comprising administering a therapeutically effective amount of a nucleic acid molecule encoding HGF directly into ~~the~~ an abdominal lateral cardiac muscle of a mammal, wherein the nucleic acid molecule is administered once a week for 8 weeks, wherein the nucleic acid molecule ~~comprises~~ is encapsulated in a Sendai virus (HVJ)-liposome and expresses an HGF protein that reduces fibrosis and/or promotes angiogenesis of the cardiac muscle, thereby treating the cardiac muscle disorder myocardiopathy.

15. (canceled)

16. (currently amended) ~~A~~ The method of claim 11, wherein the cardiac muscle disorder is angina pectoris or heart failure ~~for treating a cardiac muscle disorder, comprising administering a nucleic acid molecule encoding a polypeptide effective for the treatment of the disorder into the affected cardiac muscle using echocardiographic guidance without thoracotomy, wherein the~~

~~polypeptide is HGF that reduces fibrosis and/or promotes angiogenesis of the cardiac muscle and the nucleic acid molecule comprises a Sendai virus (HVJ) liposome.~~

17-32. (canceled)

33. (currently amended) A method for treating a cardiac muscle disorder ~~myocardiopathy~~, comprising administering a therapeutically effective amount of a nucleic acid molecule encoding HGF directly into a abdominal lateral cardiac muscle of a mammal, wherein administering comprises administering the nucleic acid molecule under echocardiographic guidance without thoracotomy through a catheter, wherein the nucleic acid molecule ~~comprises~~ is encapsulated in a Sendai virus (HVJ)-liposome and expresses an HGF protein that reduces fibrosis and/or promotes angiogenesis of the cardiac muscle, thereby treating the cardiac muscle disorder ~~myocardiopathy~~.

34-41. (canceled)